The use of oral glucocorticoids and the risk of major osteoporotic fracture in patients with myasthenia gravis

被引：0
|
作者：
Zohreh Safipour
Rogier van der Zanden
Joop van den Bergh
Paddy Janssen
Peter Vestergaard
Frank de Vries
Johanna H. M. Driessen
机构：
[1] Curaçao Medical Centre,Department of Clinical Pharmacy
[2] Maastricht University Medical Centre,Department of Clinical Pharmacy
[3] Maastricht University Medical Centre,Department of Internal Medicine
[4] Hasselt University,Faculty of Medicine and Life Science
[5] Viecuri Medical Centre,Department of Internal Medicine
[6] Viecuri Medical Centre,Department of Clinical Pharmacy
[7] Aalborg University Hospital,Departments of Clinical Medicines and Endocrinology
[8] Steno Diabetes Center North Jutland,MRC Lifecourse Epidemiology Unit
[9] Southampton General Hospital,Division of Pharmacoepidemiology and Clinical Pharmacology
[10] Utrecht Institute of Pharmaceutical Sciences,NUTRIM
[11] Cardiovascular Research Institute Maastricht (CARIM),School for Nutrition and Translational Research in Metabolism
[12] Maastricht University,undefined
来源：
Osteoporosis International | 2022年 / 33卷
关键词：
Glucocorticoids; Fracture; Bone; Myasthenia gravis; Case–control study;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：649 / 658
页数：9
相关论文
共 50 条
  • [41] The risk of infectious disease (ID) in patients with myasthenia gravis (MG)
    Mayorga, DA
    Ajiboye, P
    Grob, D
    Von Gizycki, H
    Lutwick, LI
    CLINICAL INFECTIOUS DISEASES, 2001, 33 (07) : 1118 - 1118
  • [42] MYASTHENIA-GRAVIS AFTER BMT - IDENTIFICATION OF PATIENTS AT RISK
    MELMS, A
    FAUL, C
    SOMMER, N
    WIETHOLTER, H
    MULLER, CA
    EHNINGER, G
    BONE MARROW TRANSPLANTATION, 1992, 9 (01) : 78 - 79
  • [43] Risk Factors for Developing Postthymectomy Myasthenia Gravis in Thymoma Patients
    Yamada, Yoshito
    Yoshida, Shigetoshi
    Iwata, Takekazu
    Suzuki, Hidemi
    Tagawa, Tetsuzo
    Mizobuchi, Teruaki
    Kawaguchi, Naoki
    Yoshino, Ichiro
    ANNALS OF THORACIC SURGERY, 2015, 99 (03): : 1013 - 1019
  • [44] RISK WEIGHT CALCULATION OF CANDIDATE VARIANTS FOR INCIDENT MAJOR OSTEOPOROTIC FRACTURE IN PATIENTS WITH RHEUMATIC DISEASES
    Yoshii, I.
    Sawada, N.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 511 - 512
  • [45] Impact of continuity of care on risk for major osteoporotic fracture in patients with new onset rheumatoid arthritis
    Seung Hoon Kim
    Hyunkyu Kim
    Sung Hoon Jeong
    Suk-Yong Jang
    Eun-Cheol Park
    Scientific Reports, 12
  • [46] USE OF THIAZOLIDINEDIONES AND RISK OF OSTEOPOROTIC FRACTURE: DISEASE OR DRUGS?
    Bazelier, Marloes
    Gallagher, Arlene
    Vestergaard, Peter
    Cooper, Cyrus
    de Vries, Frank
    OSTEOPOROSIS INTERNATIONAL, 2012, 23 : S556 - S556
  • [47] Risk factors for postoperative myasthenia gravis in patients with thymoma without myasthenia gravis: A systematic review and meta-analysis
    Tang, Mingbo
    Shao, Yifeng
    Dong, Junxue
    Gao, Xinliang
    Wei, Shixiong
    Ma, Jianzun
    Hong, Yang
    Li, Zhiqin
    Bi, Taiyu
    Yin, Yipeng
    Zhang, Wenyu
    Liu, Wei
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [48] The use of eculizumab in ventilator-dependent myasthenia gravis patients
    Usman, Uzma
    Chrisman, Christina
    Houston, Drew
    Haws, Clara Chow
    Wang, Alan
    Muley, Suraj
    MUSCLE & NERVE, 2021, 64 (02) : 212 - 215
  • [49] The use of intra-detrusor onabotulinumtoxinA in patients with myasthenia gravis
    Wright, Ian
    Civitarese, Andrea
    Baverstock, Richard
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2016, 10 (5-6): : E184 - E185
  • [50] Prescription profile of pyridostigmine use in a population of patients with myasthenia gravis
    Enrique Machado-Alba, Jorge
    Felipe Calvo-Torres, Luis
    Gaviria-Mendoza, Andres
    Augusto Mejia-Velez, Cesar
    MUSCLE & NERVE, 2017, 56 (06) : 1041 - 1046
12345